RARE — Ultragenyx Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $1.50bn
- $2.35bn
- $673.00m
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Amgen, Crowdstrike, Micron Technology
Ultragenyx tumbles on $400 mln Crysvita royalty sale
Rare diseases therapeutics developer Ultragenyx reaffirms 2025 revenue guidance
Brief: Ultragenyx Q3 EPS USD -1.81
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule
Brief: Ultragenyx Appoints Eric Olson As Chief Business Officer And Executive Vice President
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq
Brief: Ultragenyx Announces Positive Longer-Term Data From Phase 3 Study Of Dtx401 Aav Gene Therapy For The Treatment Of Glycogen Storage Disease Type Ia (Gsdia)
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Ultragenyx Initiates Submission Of BLA To The U.S. FDA For DTX401 AAV Gene Therapy
Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Ultragenyx Q2 EPS USD -1.17
Ultragenyx Pharmaceutical Inc expected to post a loss of $1.30 a share - Earnings Preview
US FDA declines to approve Ultragenyx's gene therapy for rare inherited disorder (updated)
US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder
Ultragenyx, Mereo tumble after update on genetic disorder drug trial data